GLYCOMIMETICS INC
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | ||
|---|---|---|---|
| | | GLYCOMIMETICS, INC. | |
| | | ||
| | | By: | /s/ Harout Semerjian |
| | | Harout Semerjian | |
| | | President and Chief Executive Officer | |
March 27, 2024
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Harout Semerjian and Brian M. Hahn, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of GlycoMimetics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | |
|---|---|---|
| Signature | Title | Date |
| | | |
| /s/ Harout Semerjian Harout Semerjian | President, Chief Executive Officer and Director(Principal Executive Officer) | March 27, 2024 |
| | | |
| /s/ Brian M. Hahn Brian M. Hahn | Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer) | March 27, 2024 |
| | | |
| /s/ Patricia S. Andrews Patricia S. Andrews | Director | March 27, 2024 |
| | | |
| /s/ Mark A. Goldberg, M.D. Mark A. Goldberg, M.D. | Director | March 27, 2024 |
| | | |
| /s/ Scott T. Jackson Scott T. Jackson | Director | March 27, 2024 |
| | | |
| /s/ Daniel M. Junius Daniel M. Junius | Director | March 27, 2024 |
| | | |
| /s/ Rachel K. King Rachel K. King | Director | March 27, 2024 |
| | | |
| /s/ Scott Koenig, M.D., Ph.D. Scott Koenig, M.D., Ph.D. | Director | March 27, 2024 |
| | | |
| /s/ Timothy Pearson Timothy Pearson | Director | March 27, 2024 |
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 75 |
|---|---|
| Balance Sheets as of December 31, 2023 and 2022 | 77 |
| Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021 | 78 |
| Statements of Stockholders’ Equity for the years ended December 31, 2023, 2022 and 2021 | 79 |
| Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 | 80 |
| Notes to Financial Statements | 81 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.